| Stock Price Details |
|
Chart |
|
|
Last Price (RS)
|
1,698.85
|
|
Change (%)
|
-27.35 (-1.58%)
|
|
Best Buy (RS)
|
0(x0)
|
|
Best Sell (RS)
|
0(x0)
|
|
Today's Range (RS)
|
1,690.00
-
1,726.20
|
|
52-Week Range (RS)
|
1,551.05
-
2,396.95
|
|
Beta (1 Year)
|
1.12
|
|
|
|
|
|
| Index Details |
| BSE 500, BSE HC, BSE SmallCap |
| News |
|
Corporate Details |
| Caplin receives USFDA approval for Desmopressin Acetate Injection |
| Caplin Point’s arm Caplin Steriles gets USFDA nod for Sodium Phosphates Injection |
| Caplin Point Laboratories consolidated net profit rises 17.93% in the December 2025 quarter |
| Caplin Point Laboratories to announce Quarterly Result |
| Volumes spurt at Honasa Consumer Ltd counter |
| Caplin Point Laboratories consolidated net profit rises 18.08% in the September 2025 quarter |
| Caplin Point Laboratories standalone net profit declines 2.98% in the September 2025 quarter |
| Caplin Point Laboratories to hold board meeting |
| Caplin Point gets USFDA approval for Nicardipine Hydrochloride injection |
| Caplin Point Laboratories Ltd - Caplin Point Laboratories Limited - Press Release |
|
|
|
| Incoporation Year : 1990 |
| Chairman : C C Paarthipan |
| Ownership Group : Indian Private |
| Sector : MAN |
| Industry : Pharmaceuticals - Indian - Formulations |
| Registered Office |
Caplin Point Laboratories Ltd
Ashvich Towers 3rd Floor,
No 3 Developed Plots Ind Estat,
Chennai,
Tamil Nadu-600096 |
Phone:91-44-24968000/71148000/28156653
Fax:91-44-28154952 |
| E-Mail : investor@caplinpoint.net; info@caplinpoint.net |
| URL : http://www.caplinpoint.net |
|
| Investor Returns |
|
| |
Date |
Price |
Returns (%) |
| 1Week |
20-Feb-2026 |
1690.75 |
0.48 |
| 1Month |
27-Jan-2026 |
1728.75 |
-1.73 |
| 3Month |
27-Nov-2025 |
1911.25 |
-11.11 |
| 6Month |
28-Aug-2025 |
2157.65 |
-21.26 |
| 1Year |
27-Feb-2025 |
1922.10 |
-11.61 |
|
|
|
|
| Mutual Funds Holding |
|
| Scheme Name |
% Holding |
Market Value (Rs Cr.) |
| UTI-Small Cap Fund |
1.47 |
66.85 |
| UTI-Large & Mid Cap Fund |
0.95 |
53.49 |
| UTI-Aggressive Hybrid Fund |
0.74 |
49.40 |
| UTI-Healthcare Fund |
2.44 |
25.72 |
| UTI Multi Cap Fund |
1.36 |
25.07 |
|
|
|
|
| Groups : Pharmaceuticals - Indian - Formulations |
|
| Company |
Last Price |
Change (%) |
52Week High |
52Week Low |
Market Cap (Rs Cr.) |
| Torrent Pharmaceuticals Ltd |
4,337.50 |
-1.42 |
4,469.35 |
2,891.45 |
146,800.71 |
| Ajanta Pharma Ltd |
2,995.00 |
0.46 |
3,052.20 |
2,022.05 |
37,418.22 |
| Gland Pharma Ltd |
1,823.00 |
-2.36 |
2,130.00 |
1,200.00 |
30,035.10 |
| Sai Life Sciences Ltd |
998.10 |
3.52 |
1,004.80 |
635.30 |
21,136.58 |
| ERIS Lifesciences Ltd |
1,359.20 |
-0.17 |
1,909.55 |
1,140.00 |
18,828.08 |
|
|
|
|